Jyong Biotech (NASDAQ:MENS) Shares Gap Up – Here’s What Happened
by Scott Moore · The Cerbat GemJyong Biotech Ltd. (NASDAQ:MENS – Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $3.17, but opened at $3.45. Jyong Biotech shares last traded at $7.46, with a volume of 11,721,070 shares traded.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jyong Biotech in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.
Jyong Biotech Stock Performance
The company has a fifty day moving average price of $33.81.
Institutional Trading of Jyong Biotech
A hedge fund recently bought a new stake in Jyong Biotech stock. BNP Paribas Financial Markets purchased a new stake in Jyong Biotech Ltd. (NASDAQ:MENS – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,698 shares of the company’s stock, valued at approximately $67,000.
Jyong Biotech Company Profile
OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.